{"product_id":"abcam-ab181260","title":"Abcam, ab181260, Anti-TPD52 antibody [EPR14219]","description":"\u003cp\u003eSize: 100µL \/ 1mL\u003cbr\u003e\nRabbit Recombinant Monoclonal TPD52 antibody. Suitable for WB, ICC\/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 2 publications.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:EPR14219,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:Flow Cyt (Intra), WB, IHC-P, ICC\/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze \/ thaw cycle\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nThe Tumor Protein D52 (TPD52) is a 224 amino acid protein also known as PrLZ or D52-like protein 1 with a mass of approximately 23 kDa. TPD52 features prominently in the regulation of cell proliferation and vesicle trafficking. It is expressed in a wide range of tissues with significant expression levels in the pancreas prostate and various cancers. TPD52 associates with other members of the D52 family proteins forming homo- or heterodimers that play a part in its function.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nTPD52 is involved in cellular processes like growth apoptosis and exocytosis. It often forms part of protein complexes assisting in intracellular signaling pathways and vesicular transport mechanisms. The ability of TPD52 to interface with other proteins such as 14-3-3 or annexins provides it with diverse functionality. Moreover its involvement in regulating secretory pathways underlines its importance in different cell types particularly those with high secretion activity.\u003cbr\u003e\nPathways\u003cbr\u003e\nTPD52 integrates into the MAPK and calcium signaling pathways. The MAPK pathway which includes key proteins like ERK1\/2 involves TPD52 in processes affecting cell growth and differentiation. TPD52 can act upstream or downstream of MAPK components indicating its dynamic role in the pathway. Similarly in calcium signaling TPD52 interacts with annexins which position it within calcium-dependent exocytotic events and cellular responses dependent on Ca2+ dynamics.\u003cbr\u003e\nTPD52 shows an association with cancers such as prostate and breast cancer. In breast cancer its overexpression correlates with rapid tumor growth and decreased patient survival rates. TPD52's link to the protein AKT suggests a role in oncogenic pathways where AKT promotes cell survival and growth. Similarly in prostate cancer altered expression levels of TPD52 may enhance tumorigenic potential and aggressiveness establishing TPD52 as a potential therapeutic target for cancer treatments.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46850388164777,"sku":"ab181260","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab181260","provider":"Iright","version":"1.0","type":"link"}